PUBLIC COMPANY
saveAstellas Pharma Inc
updated 21d ago
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. .
community read0 votes
🐶 often sniffed alongside
top 5pipeline
8
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
1
recalls ytd
0
Pipeline(8)
pipeline depth8 products
4Phase 21Marketed3Unknown
Marketed
enfortumab vedotin
Muscle Invasive Bladder Cancer (MIBC)
Nectin-4Tubulin
Phase 2ASP-2957
X-Linked Myotubular Myopathy (XLMTM or MTM)
Phase 2ASP-7316
Juvenile Macular Degeneration (Stargardt Disease)
Phase 2zocaglusagene nuzaparvovec
Pompe Disease
Phase 2zolbetuximab
Metastatic Adenocarcinoma of The Pancreas
Claudin-18
drugIZERVAY
drugPADCEV
drugXTANDI
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study of ASP3082 in Adults With Advanced Solid Tumors
- phase2A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke
- phase4A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
- phase1A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- phase3A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
- phase3A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause
- —Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
- phase1A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
🐶 Hiring Signal
News
- Kolon TissueGene cuts 37 US staffers after Phase 3 failFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- PTC takes a chance on Sangamo’s Fabry disease gene therapyWall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.biopharma_dive · 7d ago
- Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccinesSome analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to level…biopharma_dive · 8d ago
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 15d ago
- AI data becomes sticking point in biopharma dealmakingAs drug hunting gets more complex, where and how data is generated in partnerships between Big Pharmas and AI biotechs is becoming a headache for dealmakers.biospace · 29d ago
- Agenus surges on study pivot; Apnimed lines up an IPOAgenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.biopharma_dive · 1mo ago
- Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workersHundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…biopharma_dive · 3mo ago
- Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffersAs always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.fiercebiotech · 8mo ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that